Giuseppe Curigliano, ESMO President Elect, Editor-in-Chief of ESMO Open, Professor of Medical Oncology at Università degli Studi di Milano, shared by Paolo Tarantino, Vivian Saykaly Visiting Professor in Medical Oncology at McGill University Health Centre, Clinical Research Fellow at Dana-Farber Cancer Institute, Research Fellow at Harvard Medical School, on X:
“Don’t miss the data at ESMO 2026!! ”
Quoting Paolo Tarantino:
“Positive phase 3 data for adjuvant pembro +/- personalized mRNA-based neoantigen vaccine for melanoma just announced by Merck and Moderna. Welcome to the future! ”
